MRFR の調査によると、角膜架橋デバイス市場は 13.86% の堅調な CAGR を達成すると予想されます。この方法では、リボフラビン点眼薬と UV 光源の両方が使用されます。光化学反応によって、コラーゲン粒子とプロテオグリカンが接触します。円錐角膜症の罹患率の増加と一般性、および医療の枠組みの拡張がCXL デバイスの世界市場の主な推進要因になるでしょう。ただし、マインドフルネスの欠如と治療に関連する二次的影響が、市場の発展を妨げると考えられます。
高齢者人口の増加、円錐角膜症の発生、およびこの地域における主要な市場プレーヤーの集中によって、北米が市場を支配すると予想されます。 先進国で円錐角膜症患者が増加しているため、ヨーロッパで CXL デバイスの需要が高まっています。円錐角膜症の有病率の上昇とその結果としての上昇、医療技術の進歩、および CXL デバイスの需要の増加によって、市場はヨーロッパで拡大しています。
目次
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 OVERVIEW
2 MARKET INTRODUCTION
2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE
2.5 ASSUMPTIONS & LIMITATIONS
3 RESEARCH METHODOLOGY
3.1 DATA MINING
3.2 SECONDARY RESEARCH
3.3 PRIMARY RESEARCH
3.4 BREAKDOWN OF PRIMARY RESPONDENTS
3.5 FORECASTING TECHNIQUES
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
3.6.1 BOTTOM-UP APPROACH
3.6.2 TOP-DOWN APPROACH
3.7 DATA TRIANGULATION
3.8 VALIDATION
4 MARKET DYNAMICS
4.1 OVERVIEW
4.2 DRIVERS
4.2.1 INCREASING INCIDENCE AND PREVALENCE OF KERATOCONUS DISORDERS
4.2.2 IMPROVING HEALTHCARE INFRASTRUCTURE
4.3 RESTRAINTS
4.3.1 LACK OF AWARENESS REGARDING KERATOCONUS DISORDERS
4.3.2 SIDE EFFECTS ASSOCIATED WITH TREATMENT
4.4 OPPORTUNITIES
4.4.1 INCREASING PRODUCT DEVELOPMENT AND LAUNCHES
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS
5.1.1 R&D
5.1.2 MANUFACTURING
5.1.3 DISTRIBUTION & SALES
5.1.4 POST-SALES MONITORING
5.2 PORTER'S FIVE FORCES MODEL
5.2.1 THREAT OF NEW ENTRANTS
5.2.2 BARGAINING POWER OF SUPPLIERS
5.2.3 THREAT OF SUBSTITUTES
5.2.4 BARGAINING POWER OF BUYERS
5.2.5 INTENSITY OF RIVALRY
5.3 IMPACT OF COVID-19 ON THE CORNEAL CROSS-LINKING (CXL) DEVICES MARKET
5.3.1 IMPACT ON SUPPLY CHAIN
5.3.2 IMPACT ON PRODUCTION
5.3.3 IMPACT ON MARKET PLAYERS
5.4 REIMBURESEMENT SCENARIO FOR CXL PROCEDURES
6 GLOBAL RIBOFLAVIN SOLUTIONS MARKET SIZE AND STATISTICS
6.1 OVERVIEW
7 GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET, BY TYPE
7.1 OVERVIEW
7.2 STANDARD CORNEAL CROSS LINKING
7.3 CORNEAL CROSS-LINKING PLUS
7.4 ACCELERATED CROSS-LINKING
8 GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET, BY METHOD
8.1 OVERVIEW
8.2 EPITHELIUM-OFF METHOD
8.3 EPITHELIUM-ON METHOD
9 GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET, BY APPLICATION
9.1 OVERVIEW
9.2 KERATOCONUS
9.3 PELLUCID MARGINAL DEGENERATION
9.4 REFRACTIVE SURGERY ECTASIA
9.5 OTHERS
10 GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET, BY END USER
10.1 OVERVIEW
10.2 HOSPITALS
10.3 EYE CLINICS
10.4 AMBULATORY SURGICAL CENTERS
11 GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET, BY REGION
11.1 OVERVIEW
11.2 NORTH AMERICA
11.2.1 US
11.2.2 CANADA
11.3 EUROPE
11.3.1 GERMANY
11.3.2 UK
11.3.3 FRANCE
11.3.4 ITALY
11.3.5 SPAIN
11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
11.4.1 JAPAN
11.4.2 CHINA
11.4.3 INDIA
11.4.4 AUSTRALIA
11.4.5 SOUTH KOREA
11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
11.5.1 MIDDLE EAST
11.5.2 AFRICA
11.5.3 LATIN AMERICA
12 COMPETITIVE LANDSCAPE
12.1 OVERVIEW
12.2 COMPETITIVE BENCHMARKING
12.3 GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET: COMPANY SHARE ANALYSIS
12.4 MAJOR GROWTH STRATEGY IN GLOBALCORNEAL CROSS-LINKING (CXL) DEVICES MARKET
12.5 THE LEADING PLAYER IN TERMS OF NUMBER OF DEVELOPMENTS IN GLOBAL CORNEAL CROSS-LINKING (CXL) DEVICES MARKET
12.6 KEY DEVELOPMENT ANALYSIS
12.7 KEY DEVELOPMENTS & GROWTH STRATEGIES
12.7.1 PARTNERSHIP/COLLABORATION
12.7.2 MERGERS & ACQUISITIONS
13 COMPANY PROFILE
13.1 GLAUKOS CORPORATION
13.1.1 COMPANY OVERVIEW
13.1.2 FINANCIAL OVERVIEW
13.1.3 PRODUCTS OFFERED
13.1.4 KEY DEVELOPMENTS
13.1.5 SWOT ANALYSIS
13.1.6 KEY STRATEGIES
13.2 EMAGINE AG
13.2.1 COMPANY OVERVIEW
13.2.2 FINANCIAL OVERVIEW
13.2.3 PRODUCTS OFFERED
13.2.4 KEY DEVELOPMENTS
13.2.5 SWOT ANALYSIS
13.2.6 KEY STRATEGIES
13.3 IVIS TECHNOLOGIES
13.3.1 COMPANY OVERVIEW
13.3.2 FINANCIAL OVERVIEW
13.3.3 PRODUCTS OFFERED
13.3.4 KEY DEVELOPMENTS
13.3.5 KEY STRATEGIES
13.4 IROMED GROUP SRL
13.4.1 COMPANY OVERVIEW
13.4.2 FINANCIAL OVERVIEW
13.4.3 PRODUCTS OFFERED
13.4.4 KEY DEVELOPMENTS
13.4.5 KEY STRATEGIES
13.5 PESCHKE GMBH
13.5.1 COMPANY OVERVIEW
13.5.2 FINANCIAL OVERVIEW
13.5.3 PRODUCTS OFFERED
13.5.4 KEY DEVELOPMENTS
13.5.5 SWOT ANALYSIS
13.5.6 KEY STRATEGIES
13.6 AJL OPHTHALMIC S.A.
13.6.1 COMPANY OVERVIEW
13.6.2 FINANCIAL OVERVIEW
13.6.3 PRODUCTS OFFERED
13.6.4 KEY DEVELOPMENTS
13.6.5 KEY STRATEGIES
14 APPENDIX
14.1 REFERENCES
14.2 RELATED REPORTS
?
